By Daniel Park, MS, Health Content Specialist. Medically reviewed by Dr. Anika Rao, MD, Board-Certified Internal Medicine.
Last October, a woman named Rachel in suburban Denver told me something that stuck. She'd been on Henry Meds's compounded tirzepatide program for five months, was down 34 pounds, and had just gotten off a 12-minute video call with her prescriber to discuss bumping from 7.5 mg to 10 mg. "It was the first time in this whole process I actually talked to a human being who knew my chart," she said. "My last platform, I was basically texting into a void." Then she paused. "But I also can't tell you the name of the pharmacy that made my last vial. That part bugs me."
Rachel's experience captures something real about Henry Meds: a platform that does some things notably better than its competitors and other things that remain frustratingly opaque. This review breaks down what the tirzepatide program actually looks like in 2026, who it works for, and where the rough edges are.
This article is part of the FormBlends best tirzepatide telehealth providers comparison and the compounded tirzepatide complete guide.
The short version
- Henry Meds offers compounded tirzepatide on a flat monthly subscription, typically $297 to $399 depending on plan length.
- The clinical model includes live video visits at no extra charge, which is unusual at this price point.
- The platform was named in FDA warning letter coverage and Eli Lilly litigation in 2024 and 2025. Both are public record.
- Pharmacy partners aren't always disclosed upfront, though the dispensing pharmacy appears on shipped product labels.
- Flat pricing across all doses is a genuine structural advantage for patients who escalate to higher doses.
How the program actually works
You fill out an intake form: medical history, medications, weight, contraindication screening. A clinician licensed in your state reviews it. For most people the initial evaluation is asynchronous (think: doctor reads your file, sends a message), but you can request a live video visit for the first consult and at any point after that.
If approved, compounded tirzepatide ships monthly. Dose escalation starts at 2.5 mg weekly and follows the standard protocol. When you want to go up, you either message through the portal or book a video call, and a clinician reviews the request.
Here's the thing that separates Henry Meds from the cheapest competitors: live video access is baked into every plan, not locked behind a premium tier. You're also supposed to have a named clinician, someone who sees your chart repeatedly rather than a rotating cast. In practice, that relationship depends on which clinician you're assigned. Some patients report real continuity. Others say they've been reassigned mid-program without much explanation.
What you're paying
Henry Meds publishes flat monthly pricing. Current 2026 numbers:
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →- Monthly plan: roughly $399 per month, all doses
- 3-month plan: roughly $349 per month, prepaid
- 6-month plan: roughly $297 per month, prepaid
The flat-across-dose structure matters more than it might seem. On platforms that charge by dose, a patient maintaining at 10 mg or 12.5 mg can end up paying $100+ more per month than someone on the starter dose. Henry Meds charges the same whether you're on 2.5 mg or 12.5 mg. For anyone who plans to escalate (which is most people), the math tilts in Henry Meds's favor over time.
The catch: multi-month prepayment locks you in. If the platform changes pharmacies, if you have a side effect that takes you off the medication, or if you simply don't like the experience, you've already paid. Check cancellation terms on their site before committing.
Pharmacy sourcing, and what they don't tell you
Henry Meds works with multiple 503A compounding pharmacy partners. The company has historically not named all partners on its marketing pages, which is a transparency gap that matters to people who want to verify sterility testing, accreditation, or state licensure before their medication arrives.
The dispensing pharmacy does appear on the medication label. Henry Meds states publicly that products are tested for sterility and potency. Certificates of analysis aren't provided automatically in the order flow, but patients have reported getting them by asking customer service directly.
The active ingredient is tirzepatide, typically formulated in a sterile saline base with a bacteriostatic preservative.
I'll say it plainly: I think pharmacy transparency should be table stakes for any compounded GLP-1 provider. The fact that you have to ask for a COA rather than receiving one automatically is a miss, and it's one that competing platforms have already solved.
The regulatory situation
Henry Meds has drawn more regulatory and legal attention than most compounded GLP-1 platforms. Here's what's publicly documented:
FDA warning letters: The FDA's compounded GLP-1 enforcement activity in 2024 and 2025 included warning letters to multiple platforms and compounding pharmacy partners. Specific letters are searchable in the FDA warning letter database. Patients should verify current status directly rather than relying on any platform's self-reported compliance claims.
Eli Lilly litigation: Lilly filed lawsuits against several compounded GLP-1 telehealth providers in 2024 and 2025, alleging trademark infringement and false advertising related to comparisons with Mounjaro and Zepbound. Henry Meds was named in some of this litigation. Cases remain ongoing as of early 2026, and dockets are available on PACER.
State pharmacy board actions: Some compounding pharmacies that have supplied Henry Meds (and other platforms) have had state pharmacy board observations. State board records are public.
What does this mean for you as a patient? It doesn't automatically make Henry Meds unsafe. But it does mean the platform operates in a spotlight, and that regulatory developments could affect supply continuity or program structure with relatively little notice. If you're prepaying for six months, that's worth factoring in.
What's included and what's missing
Included:
- Online intake and clinician chart review
- Live video visits with your assigned clinician (patient-initiated, no extra fee)
- Compounded tirzepatide shipped monthly
- Syringes and supplies
- Patient portal with clinical messaging
- Dose escalation reviews
Not included:
- Lab work or ongoing metabolic monitoring
- Structured coaching programs
- Dietitian access
- Insurance billing for the compounded product
The live video access is the standout inclusion. If you want to ask about a side effect at 3 a.m., you're still limited to async messaging. But for a scheduled conversation about whether to escalate, how to manage nausea, or whether a new medication interacts with tirzepatide, you can get a real call. That's genuinely different from async-only platforms where clinical interaction amounts to filling out forms and waiting.
The missing piece that stands out: no lab monitoring. Tirzepatide affects blood sugar, lipids, and potentially thyroid and pancreatic markers. A responsible weight loss program should at minimum prompt you to get baseline labs and periodic follow-ups. Henry Meds leaves that entirely to you and your primary care doctor.
State coverage and shipping
Henry Meds ships to most U.S. states, though the list has shifted as compounded GLP-1 regulations evolve at the state level. A handful of states have been excluded at various times. Current coverage is shown at checkout.
How it stacks up against alternatives
Versus Hims: Henry Meds offers a more synchronous clinical model with included live visits at a higher price. Hims is cheaper at the starter dose but price escalates with dose. For patients who plan to stay at 10 mg or higher long-term, Henry Meds's flat pricing can actually be comparable or cheaper. See the Henry Meds vs Hims comparison for the full side-by-side.
Versus Mochi Health: Mochi includes coaching and dietitian access at a similar or higher price. Henry Meds focuses on clinical access without the wellness layer.
Versus Eden or ShedRx: Cheaper async-only platforms with lower starter pricing but less clinical interaction.
Versus FormBlends: FormBlends names the dispensing pharmacy, provides certificates of analysis on request, and runs synchronous clinical review. Pricing is comparable. The trade-off is in transparency and clinical structure.
What patients actually say
Patient reviews on independent forums cluster around three themes. Positive: clinical access and flat pricing are consistently valued. Mixed: pharmacy partner changes have caused some patients to receive product from a different pharmacy than they started with, which feels like getting a different brand of your medication without being told. Negative: support response times have varied, and some patients report pharmacy supply interruptions during periods of high regulatory activity.
Trustpilot and similar aggregators skew positive, with the usual caveats about review platforms in general.
Who this is actually for
A good fit: someone who wants compounded tirzepatide from an established platform, values being able to talk to a clinician on camera, prefers flat pricing through dose escalation, and is comfortable with the regulatory profile of a high-visibility provider in a contested space.
Less ideal: patients with significant comorbidities who need lab monitoring and structured ongoing care, patients shopping purely on price, and patients who consider pharmacy transparency a prerequisite rather than a nice-to-have.
The clinical data behind tirzepatide
The case for tirzepatide rests on SURMOUNT-1 (Jastreboff et al., NEJM 2022), which evaluated tirzepatide in adults with obesity and reported mean weight loss of approximately 15% to 22% at maintenance doses over 72 weeks. SURMOUNT-2 (Garvey et al., Lancet 2023) extended these findings to adults with obesity and type 2 diabetes. These data apply to the FDA-approved branded drug Zepbound. They apply to compounded tirzepatide only by inference, based on shared active ingredient. Compounded products were not studied in the SURMOUNT trials.
Frequently asked questions
Is Henry Meds legit?
Henry Meds is a licensed telehealth platform with prescribing clinicians and compounding pharmacy partners. It has drawn FDA and litigation attention in 2024 and 2025, which is publicly documented. "Legit" in the regulatory sense, yes. Whether the regulatory profile is acceptable to you is a personal judgment call.
How much is Henry Meds tirzepatide per month?
Current pricing runs roughly $297 to $399 per month depending on plan length, flat across all doses.
Does Henry Meds tell you which pharmacy makes the tirzepatide?
Not on the marketing page. The dispensing pharmacy appears on the medication label. Patients can request more information through customer service.
Does Henry Meds offer Zepbound or only compounded?
Henry Meds's primary offering is compounded tirzepatide. Branded Zepbound is not a core program offering.
Has Henry Meds been in any lawsuits?
Henry Meds has been named in compounded GLP-1 litigation, including Eli Lilly's broader 2024 and 2025 enforcement actions against compounded GLP-1 marketers. Public dockets are available on PACER.
Can I cancel Henry Meds anytime?
Cancellation policy varies by plan. Multi-month prepaid plans have specific terms. Verify on Henry Meds's site before signing up.
Is Henry Meds tirzepatide the same as Zepbound?
The active ingredient is tirzepatide in both cases. Compounded tirzepatide is not FDA-approved and is not considered therapeutically equivalent to Zepbound in the regulatory sense.
Continue the series
- Hub: Best Tirzepatide Telehealth Providers 2026
- Comparison: Henry Meds vs Hims for Tirzepatide
- Related: Mochi Health Tirzepatide Review
- Pillar: Compounded Tirzepatide Complete Guide
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends is not a medical practice. FormBlends sells only compounded tirzepatide and compounded semaglutide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber.
About this article
Written by Daniel Park, MS (Health Content Specialist). Medically reviewed by Dr. Anika Rao, MD (Board-Certified Internal Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. Provider details are based on publicly available information as of early 2026 and may change. Always verify current pricing and program details on the provider's own site.